Mathews Journal of Case Reports

2474-3666

Current Issue Volume 9, Issue 3 - 2024

Briefly towards Biomarker-Driven Development and Their Global Impact in the Personalized and Precision Healthcare-Related Clinical Practice

Sergey Suchkov1-6,9,*, Daniel Scherman10, Alan Wu15,16, Shawn Murphy7,8, David Smith11, Hiroyuki Abe9, Holland Cheng12, Lidiia Sysoeva1, Philip D. Cotter13, John Aitken14, Steven Dooley15

1Department for Clinical Allergology & Immunology of the Russian University of Medicine, Moscow, Russia

2The Russian Academy of Natural Sciences, Moscow, Russia

3EPMA, Brussels, EU

4PMC, Washington, USA

5AMEE, Dundee, Scotland

6AHA, Houston, TX, USA

7MGH, Boston, MA, USA

8Harvard Medical School, Boston, MA, USA

9ISPM, Tokyo, Japan

10Centre de Recherche Pharmaceutique de Paris (CRP2); Faculté de Pharmacie, Université Paris Descarte, Centre National de la Recherche Scientifique, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS) Inserm, Paris, France

11Mayo Clinic, Rochester, MN, USA

12T College of Biological Sciences, UC Davis, CA, USA

13ResearchDx and PacificDx, Irvine, CA, USA

14Otakaro Pathways, Christchurch, New Zealand

15Medizinische Fakultät Mannheim der Universität Heidelberg II. Medizinische Klinik Molekulare Hepatologie, Germany

*Corresponding Author: Prof. Sergey Suchkov, Department for Clinical Allergology & Immunology of the Russian University of Medicine, Moscow, Russia, Tel: 89857616567, Email: [email protected].

Received Date: February 18, 2024

Published Date: March 15, 2024

Citation: Suchkov S, et al. (2024). Briefly towards Biomarker-Driven Development and Their Global Impact in the Personalized and Precision Healthcare-Related Clinical Practice. Mathews J Case Rep. 9(3):159.

Copyrights: Suchkov S, et al. © (2024).

ABSTRACT

Personalized and precision medicine relies on specific biomarkers to guide clinical decisions, distinguishing between predictive and prognostic biomarkers. Biomarkers are crucial in diagnosis, risk assessment, treatment guidance, and monitoring, with the potential to improve treatment outcomes. Biomarkers are clinically significant to a wide range of medical conditions, including cardiovascular diseases, autoimmune disorders, and neurodegenerative diseases. In cancer research, biomarkers enable risk assessment, diagnosis, prognosis determination, treatment prediction, therapy monitoring, and revolutionizing clinical decision-making. Designing trials for biomarker-guided therapy presents numerous challenges. Despite these, biomarker-guided trials are crucial for advancing personalized medicine and improving patient outcomes. New generation of biomarkers, particularly microRNAs are gathering attention into the realm of personalized and precision medicine due to their diagnostic, prognostic, and predictive biomarker potential. However, new types of biomarkers need to be researched and implemented to harness this potential. Additionally, this article discusses the integration of biomarkers into clinical practice, the direction of potential research, and the transformative impact new types of biomarkers can have on personalized medicine. Ultimately, the article emphasizes the significance of biomarker research in advancing personalized healthcare interventions, improving patient outcomes, and reshaping the healthcare landscape.

Keywords: Biomarker, Biomarker classification, Clinical trial, Companion diagnostics (CDx), Drug development, Personalized and Precision Medicine, Personalized treatment, Biodesign, Predictive biomarker, Prognostic biomarker.


Creative Commons License

© 2015 Mathews Open Access Journals. All Rights Reserved.

Open Access by Mathews Open Access Journals is licensed under a
Creative Commons Attribution 4.0 International License.
Based On a Work at Mathewsopenaccess.com